3CL^pro^3C-like protease;ACE2Angiotensin-converting enzyme 2;ARDSAcute respiratory distress syndrome;CC~50~Cytotoxic concentration;CD13Human aminopeptidase N receptor;COVID-19Corona virus disease 2019;DPP4Dipeptidyl peptidase 4;Nsp3Non-structural proteins proteases 3;EC~50~Half maximal effective concentration;EREndoplasmic reticulum;EtOHEthanol;EtOAcEthyl acetate;FDAFood and Drug Administration;HCoV-229EHuman coronavirus 229E;HCoV-HKU1Human coronavirus Hong Kong University 1;HCoV-NL63Human coronavirus NL63;HCoV-OC43Human coronavirus OC43;HIVHuman immunodeficiency Virus;IC~50~Half maximal inhibitory concentration;IL-6Interleukin 6;IL-6RInterleukin-6 receptor;MERS-CoVMiddle East Respiratory Syndrome Coronavirus;MHV-A59Coronavirus Murine hepatitis virus;NUnaltered natural product;NDNatural product derivative;Nsp5Non-structural proteins proteases 5;ORF1a/bNonstructural open‐reading frames;RdRpRNA dependent RNA polymerase;RNARibonucleic acid;SARS-CoVSevere acute respiratory syndrome coronavirus;SARS-CoV-2Severe acute respiratory syndrome coronavirus 2;TEMTransmission electron microscope.

Introduction {#sec0001}
============

Coronaviruses were isolated in 1965 from the respiratory tract of adult humans with common cold symptoms ([@bib0060]). At the beginning, the endemic corona viruses such as: HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 caused mild upper respiratory disease in humans ([@bib0013]). In the past two decades coronaviruses have appeared on a large pandemic scale displayed by the appearance of the severe acute respiratory syndrome virus (SARS-CoV) followed by the other types of Coronaviruses (MERS-CoV) ([@bib0011]). The severe respiratory syndrome virus reached many countries and affected many people after crossover from animal (bats as a natural reservoir host) to human, causing high fatality rates ([@bib0152]). The novel SARS-CoV-2 belongs to the coronavirus family that appears to have originated from bats with unknown intermediate host (s) ([@bib0031]).

Nowadays, the incidence and spread of the new coronavirus disease 2019 (COVID-19) in Wuhan City, Hubei province in China became a threat to the world and a recent public health crisis ([@bib0117]). On the 11^th^ of February 2020 the International Committee on Taxonomy of Viruses called it the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ([@bib0021]). The primary causative factor of infection transmission is the direct contact with patients such as: handshakes, contaminated surfaces and indirect inhalation of infected respiratory droplets, hence the incubation period which should be enforced around 14 days ([@bib0021]; [@bib0119]).

The usual clinical signs are manifested as: dry cough, fever, headache, pneumonia, and breathing difficulties (dyspnea). Subsequently, the respiratory infection causes alveolar damage and respiratory failure, additionally, a decrease in the number of white blood cells, especially lymphocytes, was observed which, all in all, can lead to death in some cases ([@bib0156]). The virus spread from China to other countries such as South Korea, Italy, Iran, USA, which, combined with the increasing incidence of infections worldwide made the World Health Organization (WHO) classify COVID-19 as a pandemic disease ([@bib0064]; [@bib0158]). The recent update from the WHO on the 14^th^ of July 2020, confirmed a total around 12 million infected cases and more than 500,000 deaths reported in different regions and countries ([@bib0136]).

Since a long time, alternative herbal medicines have been used as a rich source for developing antiviral drugs ([@bib0082]). For instance, the Chinese herbal medicine was applied as the frontline remedies towards mild and moderate cases of COVID-19 infections. Based on the historical records of Chinese herbal medicine in preventing and treating several health ailments, *Glycyrrhiza*, bitter almond, gypsum, *Trichosanthes*, reed root, amomum, and ephedra were highly recommended to relieve cough, remove toxicity, increase immunity, and combat the fever of the admitted patients (S. [@bib0129]). Similarly, many purified natural products have been administrated as anti-coronavirus. For instance, phenolic compounds isolated from *Isatis indigotica* and amentoflavone isolated from *Torreya nucifera* work as a 3CL protease inhibitor and were used against SARS-CoV earlier. While saikosaponins B2 isolated from *Bupleurum* spp. was utilized against HCoV-229E and known to inhibit the viral attachment to host cells ([@bib0019]; [@bib0056]). Furthermore, neem tree extract was used to help improve the immune system ([@bib0108]). The traditional medicinal herbs were described by the Chinese medical health care system in more than 23 provinces in China as alternatives for the prevention and treatment of the COVID-19 virus ([@bib0089]). The main aim of this review is to highlight the role of natural products especially, plants, microorganisms, marines, and/or their derivatives as a promising drug lead against different species of coronaviruses.

Coronaviruses {#sec0002}
=============

Coronaviruses types and classifications {#sec0003}
---------------------------------------

Human coronaviruses (CoVs) are enveloped viruses, classified into seven types namely HCoV-229E, HCoV-NL63, HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV and SARS-CoV-2 (COVID-19) ([Fig. 1](#fig0001){ref-type="fig"} ) ([@bib0026]; [@bib0106]). The first two CoVs were reported in 1960's, followed by the discovery of four other types in the 1970's ([@bib0070]). The first four have been accompanied by symptoms such as the common cold, cough, fever, nasal congestion, sore throat, sneezing, and neurological diseases ([@bib0128]; [@bib0135]). Their distribution was related mainly to temperate climates during the winter and spring months but geographically they have been observed all over the world ([@bib0122]). HCoV-229E entered cells *via* binding to the aminopeptidase N receptor (CD13) found on the surface ([@bib0150]). The incubation period ranged between 2-5 days ([@bib0073]). The HCoV-229E virus replicated in the epithelial cell line of the trachea ([@bib0115]). The First isolation for the HCoV-NL63 type was observed in a 7-month-old baby in early 2004 ([@bib0040]). Different clinical evidences were reported and showed that HCoV-NL63 induced similar symptoms to those associated with HCoV-229E and HCoV-OC43 ([@bib0122]). Since HCoV-NL63 and HCoV-229E can share 65% of their amino acid identity, they have an identical mechanism of cellular entry ([@bib0125]).Fig. 1Different types of coronavirus (CoVs) and their pathogenesisFig 1

Severe Acute Respiratory Syndrome Coronavirus (SARS CoV) disproportionately infected adults, with notable severe symptoms *i.e.* fever, chills, myalgia, malaise, and headache, followed by a non-productive cough and dyspnea 3-5 days later ([@bib0041]; [@bib0124]). SARS-CoV was also named atypical pneumonia and was recorded as the first pandemic virus in human history ([@bib0105]). Its incubation period is 2-10 days ([@bib0138]). Young children and infants infected with SARS-CoV suffered from less severe symptoms than youth and adults ([@bib0008]). Infection with SARS-CoV type started by the inoculation of respiratory tract mucosa through Angiotensin-converting enzyme 2 ([@bib0078]). Middle East Respiratory Syndrome Coronavirus (MERS-CoV) rarely infected children, but it can cause severe infections for youth. Infected cases with MERS-CoV suffered from many symptoms *i.e.* fever, cough, chills, sore throat, myalgia, arthralgia, dyspnea, pneumonia, diarrhea and vomiting ([@bib0003]). It was isolated for the first time in a Saudi Arabian patient in 2012, then in another case from South Korea in 2015. About 2500 fatality cases were reported in February 2020 ([@bib0043]; [@bib0051]; [@bib0149]). Its incubation period ranged from 2-13 days ([@bib0025]). MERS-CoV infection started with inoculation of the respiratory tract mucosa mediated by functional receptors such as dipeptidyl peptidase 4 (DPP4) ([@bib0095]). Then the world faced a new challenge in December 2019, starting with the recording of the first SARS-CoV-2 case in Wuhan, Hubei province, China ([@bib0052]). The statistics reported on the of 14^th^ July 2020, confirmed that the number of fatality cases reached 570288 total cases worldwide ([@bib0136]). SARS-CoV-2 causes severe respiratory infection accompanied by different symptoms *i.e.* fever, cough, dyspnea, myalgia, and headache ([@bib0052]). SARS-CoV-2 is mostly less pathogenic, but spreads more compared to SARS-CoV and MERS-CoV ([@bib0156]).

SARS-CoV-2 Origin, Taxonomy and Structure {#sec0004}
-----------------------------------------

In Wuhan, the capital of central China\'s Hubei province, the Coronavirus (COVID-19) outbreak appeared at the end of 2019, where China\'s Infectious Disease Information System recorded the first case on December 8, 2019 ([@bib0004]; [@bib0142]). The city\'s Huanan Seafood Market was the origin of the zoonotic virus SARS-CoV-2 which was transferred rapidly ([@bib0012]). The recent phylogenetic analysis detected that SARS-CoV-2 may be evolved from a strain found in bats, thus considered the natural reservoir host of SARS-CoV-2 (H. [@bib0016]; [@bib0156]). Till now, the researchers are not sure about the intermediate host(s) of SARS-CoV-2 or whether the infection can be transmitted directly from bat to human ([@bib0149]). It was then recognized as worldwide pandemic disease that can be transmitted rapidly between humans through droplets or direct contact (Z. [@bib0076]).

2019-nCoV (COVID-19; also named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel member of the coronaviruses ([@bib0131]). Nevertheless, it has a specific gene sequence that differentiates it from previously sequenced coronaviruses ([@bib0156]). Interestingly, it has an 88% shared identity with SARS-CoV and about 50% to MERS-CoV, indicating that it belongs to the same species (H. [@bib0016]; [@bib0088]). The phylogenetic analysis done to classify SARS-CoV-2 revealed that it falls into the Sarbecovirus subgenus of the genus Betacoronavirus ([@bib0088]; [@bib0157]).

In general, HCoVs are long and positive single stranded RNA viruses characteristic of two groups of proteins; the first group is namely the structural proteins: Spike (S), Nucleocapsid (N), Matrix (M), and Envelope (E) ([Fig. 2](#fig0002){ref-type="fig"} ), while the second group is non-structural proteins: proteases (nsp3 and nsp5) and RdRp (nsp12) ([@bib0038]). In the case of SARS-CoV-2, the densely glycosylated spike protein found on the outer surface is arranged in this way in order to facilitate the recognition, attachment, and entry into the host cell ([@bib0053]). Similarly, the genetic material of SARS-CoV-2 is a positive sense RNA strand ([@bib0021]). SARS-CoV-2 was described with a transmission electron microscope (TEM) where the double-wall surface of SARS-CoV-2 was seen, but it gives only a poor description of the different organelles in the cytoplasm ([@bib0021]; [@bib0127]). Thus, it was assumed that SARS-CoV-2 has distinct ultrastructural features similar to the coronavirus family such double-membrane vesicles, large granular areas of cytoplasm and nucleocapsid inclusions, in addition to viral proteins and genetic material RNA ([@bib0021]).Fig. 2Illustrating the structure of SARS-CoV-2 (COVID-19).Fig 2

Replication, pathogenesis and transmission {#sec0005}
------------------------------------------

SARS-CoV and SARS-CoV-2 (COVID-19) are similar in the mechanism of replication ([@bib0049]). Its replication begins with the binding of its spike protein (S) into the host\'s cell surface molecules ([@bib0112]). Usually, (S) protein is divided functionally into the S1 domain, responsible for binding to human receptors, and the S2 domain is responsible for cell membrane fusion ([@bib0050]). SARS-CoV-2 enters the host cells through recognition of human receptor angiotensin-converting enzyme 2 (ACE2) ([@bib0156]). RNA material of SARS-CoV-2 undergoes replication and transcription after the fusion with the plasma membrane. Replicase proteins of SARS-CoV-2 are generated from translation of positive sense RNA genomes through open reading frame 1a/b (ORF1a/b). These proteins use positive sense RNA as a template to generate full-length negative sense RNA. Then proteins are collected with new RNA genome assembly in the endoplasmic reticulum (ER) and Golgi-apparatus ([Fig. 3](#fig0003){ref-type="fig"} ) ([@bib0049]). Biophysical and structural analysis confirmed that the S protein of SARS-CoV-2 has an affinity to bind with ACE2 about 10-20 times higher than the S protein of SARS-CoV ([@bib0139]). The high affinity of the S protein for human ACE2 can facilitate the spread of SARS-CoV-2 between humans ([@bib0156]).Fig. 3Mechanism of SARS-CoV-2 replicationFig 3

The studies conducted on the COVID-19 infection mechanism showed an increase in leukocyte levels, plasma pro-inflammatory cytokines *i.e.* IL-6, and blood C-reactive protein values from the normal range ([@bib0072]). Lower numbers of T and B lymphocytes in peripheral blood are observed and coagulation parameters *i.e.* D-Dimer raise abnormally ([@bib0083]). The main pathogenesis of the COVID-19 infection is described as extreme pneumonia, RNAaemia, and acute cardiac injury ([@bib0052]). The high rate of renal failure was observed in patients with COVID-19, suggesting the development of renal dysfunction (Q. [@bib0076]; Z. [@bib0076]).

The human-to-human spread is now the primary way of transmission of the infection; from both symptomatic and asymptomatic individuals. The transmission from symptomatic patients occurs to nearby individuals but does not occur through air. Transmission from asymptomatic individuals occurs through direct contact, handshaking ([@bib0062]), touching contaminated surfaces ([@bib0004]) or droplets spread by coughing or sneezing then touching the mouth, nose or eyes ([@bib0101]). Therefore, the human-to-human transmission depends on proximity and increased population density. Also, [@bib0074] proved that inadequate use of masks could lead to increased chances of infection transmission ([@bib0074]). A study conducted by [@bib0016] on confirmed pregnant women cases, demonstrated no evidence of trans-placental transmission. These women underwent cesarean sections, so the transmission by vaginal birth is still under debate (H. [@bib0016]).

In the previous years, SARS-CoV (2003) infected about 8098 individuals in 26 regions around the world with a mortality rate of 9% ([@bib0138]). On the other hand, SARS-CoV-2 has infected roughly 7690708 individuals in more than 200 countries until the 14^th^ of June 2020 ([@bib0137]). Meaning that the transmission of SARS-CoV-2 is higher than SARS-CoV. [@bib0076] proved that the high spread of COVID-19 is due to the genetic recombinant S protein (Q. [@bib0076]). Initial reports identified two species of snakes that may be a reservoir of SARS-CoV-2 ([@bib0058]; [@bib0110]). Mammals or birds are the only evidenced reservoirs of SARS-CoV-2 ([@bib0006]). Genomic sequence analysis of SARS-CoV-2 showed an 88% identity share with two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses ([@bib0012]; [@bib0088]; Y. [@bib0129]). Despite the fact that the genetic material of SARS-CoV-2 is compatible with other types of coronavirus, its gene sequences remarkably differ from previous sequences of other CoV types ([@bib0156]). The genetic studies of SARS-CoV-2 showed that its sequence shared 79% identity with the other CoVs types ([@bib0088]).

rational use of natural products based antiviral agents {#sec0006}
=======================================================

1. Drugs management in preclinical studies (*in vivo, in vitro*) {#sec0007}
----------------------------------------------------------------

Despite huge efforts, the world has been unable to discover potential therapies or vaccines against COVID-19, thus most of the scientific efforts are now allocated towards trying to locate a proper medication from the old conventional drugs applied earlier for previous coronavirus varieties, among them are HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1 which caused mild upper respiratory disease in humans, as well as severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV ([@bib0106]). Natural products, mainly plants, remain as a rich source of novel therapeutic agents for the treatment of different human illnesses ([@bib0145]). In this context, many natural product derivative therapeutic agents have been reported to inhibit entry and replication of many coronaviruses; SARS, MERS, etc\... (*in vitro* and *in vivo*) ([Tables 1](#tbl0001){ref-type="table"} and [2](#tbl0002){ref-type="table"} ; [Fig. 4](#fig0004){ref-type="fig"} -[6](#fig0006){ref-type="fig"} )Table 1List of isolated anti-viral natural products compounds and their derivativesTable 1Compound name, chemical classOriginMechanism of actionVirus typeIC~50~ or EC~50~ (CC~50~) value µg/mlReference**Plants**2,3,4,6,7-pentamethoxy-12,13-dihydro-11*H* dibenzo\[*f,h*\]pyrrolo- \[1,2-*β*\] isoquinolin-10ium (ND), alkaloid **(1)***Ficus septica* L.Inhibits viral replicationTGEV14.906±2468 (\>100,000) nM(C.-W. Yang et al., 2010)3,14α-dihydroxy-4,6,7-trimethoxyphenanthroindolizidine (ND), alkaloid **(2)***T. ovata* L.Inhibits viral replicationTGEV8±2 (59.943±2786) nM(C.-W. Yang et al., 2010)3,14α -dihydroxy-6,7-dimethoxyp-henanthroindolizidine (ND), alkaloid **(3)***T. ovata* L.Inhibits viral replicationTGEV18±1 (31,632±1192) nM(C.-W. Yang et al., 2010)3′-*O*-methyldiplacol (N), flavonoid **(4)***Paulownia tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV9.5±0.10 µM(Cho et al., 2013)3′-*O*-methyldiplacone (N), flavonoid **(5)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV13.2±0.14 µM(Cho et al., 2013)3′-(3-methylbut-2-enyl)-3′,4,7-trihydroxyflavane (N), flavonoid **(6)***Broussonetia papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV48.8±6.6 µM(Park et al., 2017)SARS-CoV30.2±6.8 µM3*β*,12-diacetoxyabieta-6,8,11,13-tetraene (N), diterpenoid **(7)***Juniperus formosana* L.Inhibits viral replicationSARS-CoV1.57 (303.3) µM(Wen et al., 2007)4\`-Hydroxychalcone (ND), flavonoid **(8)***Cinnamomum* spp.Inhibits viral replicationHCoV-OC431.52 (\>20) µM(Jarvill-Taylor et al., 2001; Orlikova et al., 2011; Shen et al., 2019)HCoV-NL637.25 (\>20) µMMERS-CoV10.23 (\>20) µMMHV-A599.75 (\>20) µM4\`-*O*-methyldiplacol (N), flavonoid **(9)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV9.2±0.13 µM(Cho et al., 2013)4\`-*O*-methyldiplacone (N), flavonoid **(10)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV12.7±0.19 µM(Cho et al., 2013)4-hydroxyisolonchocarpin (N), flavonoid **(11)***B. papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV171.6±10.2 µM(Park et al., 2017)SARS-CoV202.7±3.9 µM6,7-dehydroroyleanone (N), diterpenoid **(12)***Chamaecyparis obtusa*\
var. *formosana*Inhibits viral replicationSARS-CoV5.55 (89.7) µM(Wen et al., 2007)6-geranyl-4′,5,7-trihydroxy-3′,5′-\
Dimethoxyflavanone (N), flavonoid **(13)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV13.9±0.18 µM(Cho et al., 2013)7*β* -hydroxydeoxycryptojaponol (N), diterpenoid **(14)***C. japonica* L.Inhibits viral replicationSARS-CoV1.15 (127) µM(Wen et al., 2007)8 *β*-hydroxyabieta-9(11),13-dien-12-one (N), diterpenoid **(15)***C. obtuse* var. *formosana*Inhibits viral replicationSARS-CoV1.47 (\>750) µM(Wen et al., 2007)Acetyl-*O*-methyltylophorinidine (ND), alkaloid **(16)***T.indica* L.Inhibits viral replicationTGEV403 ± 22 (\>100,000) nM(Govindachari et al., 1973; C.-W. Yang et al., 2010)Aloeemodin (N), anthraquinone **(17)***Isatis indigotica*Inhibits enzymatic activity of virusSARS-CoV366 (11592) µM(Lin et al., 2005)Baicalin (N), flavonoid **(18)***Scutellaria baicalensis*Inhibits the enzymatic activitySARS-CoV\
12.5-25\
(\>100) µg/ml(Chen et al., 2004; Deng et al., 2012)Berbamine (N), bis-benzylisoquinoline alkaloids **(19)***Berberis amurensis*Inhibits viral replicationHCoV-OC431.48 (\>20) µM(Meng et al., 2013; Shen et al., 2019)HCoV-NL639.46 (\>20) µMMERS-CoV13.14 (\>20) µMMHV-A5910.91 (\>20) µMBeta-sitosterol (N), steroid **(20)***I. indigotica*Inhibits enzymatic activity of virusSARS-CoV1210 (1475) µM(Lin et al., 2005)Betulonic acid (N), triterpene **(21)***J. formosana* L.Inhibits viral replicationSARS-CoV0.63 (112) µM(Wen et al., 2007)Broussochalcone A (N), polyphenol **(22)***B. papyrifera*tInhibits coronavirus proteases enzymeMERS-CoV42.1±5.0 µM(Park et al., 2017)SARS-CoV88.1±13.0 µMBroussochalcone B (N), polyphenol **(23)***Broussonetia papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV112.9±10.1 µM(Park et al., 2017)SARS-CoV57.8±0.5 µMBroussoflavan A (N), flavonoid **(24)***B. papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV49.1±7.5 µM(Park et al., 2017)SARS-CoV92.4±2.1 µMCedrane-3 *β*,12-diol (N), sesquiterpenoid **(25)***J. formosana* L.Inhibits viral replicationSARS-CoV\>10 (\>750) µM(Wen et al., 2007)Cepharanthine, (N), (bis-benzylisoquinoline alkaloids) **(26)***S. tetrandra*Inhibits viral S and N protein expression/ Suppressed the replicationHCoV-229E729.7 nM(Kim et al., 2019)Chloroquine (S\*), alkaloid **(27)***Cinchona* spp*.*\
Inhibits viral replicationHCoV-OC430.33 (\>20) µM(Keyaerts et al., 2009; Oliveira et al., 2009; Shen et al., 2019)HCoV-NL634.89 (\>20) µMMERS-CoV16.44 (\>20) µMMHV-A5915.92 (\>20) µMSARS-CoV8.8±1.2 µMConessine (N), steroid alkaloid **(28)***Holarrhena antidysenterica*Inhibits viral replicationHCoV-OC432.34 (\>20) µM(Dua et al., 2013; Shen et al., 2019)HCoV-NL6310.75 (\>20) µMMERS-CoV4.98 (\>20) µMMHV-A5911.46 (\>20) µMCryptojaponol (N), diterpenoid **(29)***Cryptomeria japonica* L.Inhibits viral replicationSARS-CoV\>10 (78.5) µM(Wen et al., 2007)Dehydroabieta-7-one, (N), diterpenoid **(30)***C. obtuse* var *formosana*Inhibits viral replicationSARS-CoV4 (305.1) µM(Wen et al., 2007)Emetine dihydrochloride hydrate (S\*), alkaloid **(31)***Carapichea ipecacuanha* L.Inhibits RNA, DNA, and protein synthesisHCoV-OC430.30 (2.69) µM(Dyall et al., 2017; Pillaiyar et al., 2020; Shen et al., 2019)HCoV-NL631.43 (3.63) µMMERS-CoV0.34 (3.08)/ 0.014 µMMHV-A590.12 (3.51) µMSARS-CoV0.05 µMFangchinoline, (N), (Bis-benzylisoquinoline alkaloids) **(32)***S. tetrandra*Inhibits viral S and N protein expressionHCoV-229E919.2 nM(Kim et al., 2019)Ferruginol, (N), diterpenoid **(33)***C. obtuse* var. *formosana*Inhibits viral replicationSARS-CoV1.39 (80.4) µM(Wen et al., 2007)Glycyrrhizin (N), terpenoid saponin **(34)***Glycyrrhiza glabra*[L](https://en.wikipedia.org/wiki/Carl_Linnaeus){#interref0001}.\
Inhibits replication, adsorption and penetration of the virus at early steps of the replicative cycleSARS-CV300 mg/L(Cinatl et al., 2003)Harmine (N), alkaloid **(35)***Peganum harmala*Inhibits viral replicationHCoV-OC431.90 (\>20) µM(Moloudizargari et al., 2013; Shen et al., 2019)HCoV-NL6313.46 (\>20) µMMERS-CoV4.93 (\>20) µMMHV-A5913.77 (\>20) µMHesperetin, (N), flavonoid **(36)***Citrus aurantium*Inhibits viral replicationSARS-CoV\
8.3 (2718 µM)(Lin et al., 2005)Hinokinin (N), lignoid **(37)**\
*C. obtuse* var.Inhibits viral replicationSARS-CoV\>10 (\>750) µM(Wen et al., 2007)Indigo (N), alkaloid **(38)***I. indigotica*Inhibits enzymatic activity of virusSARS-CoV752 (7375) µM(Lin et al., 2005)Indirubin (N), alkaloid **(39)***I. indigotica*Inhibits enzymatic activity of virusSARS-CoV-(Lin et al., 2005)Kazinol A (N), flavonoid **(40)***B. papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV88.5±3.9 µM(Park et al., 2017)SARS-CoV84.8±10.4 µMKazinol B (N), flavonoid **(41)***B. papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV94.9±13.1µM(Park et al., 2017)SARS-CoV233.3±6.7 µMKazinol F (N), flavonoid **(42)***B. papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV39.5±5.1 µM(Park et al., 2017)SARS-CoV43.3±10.4 µMKazinol J (N), flavonoid **(43)***B. papyrifera*Inhibits coronavirus proteases enzymeMERS-CoV55.0±1.3 µM(Park et al., 2017)SARS-CoV64.2 ± 1.7 µMLuteolin (N), flavonoid **(44)***Rhodiola kirilowii* L.Inhibits entry of virus to cellSARS-CoV\
10.6 µM (0.155) mM(Yi et al., 2004)Lycorine (N), alkaloid **(45)***Lycoris radiata* (L\'Hér.)Inhibits cell division, antineoplastic, antiviralHCoV-OC430.15 (4.37) µM(Li et al., 2005; Pillaiyar et al., 2020; Shen et al., 2019)HCoV-NL630.47 (3.81) µMMERS-CoV1.63 (3.14) µMMHV-A590.31 (3.51) µMSARS-CoV0.0157 (14.98) µMMimulone (N), flavonoid **(46)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV14.4±0.27 µM(Cho et al., 2013)N-acetylglucosamine (N), alkaloid **(47)***Urtica dioica*\
agglutininInhibits viral replicationSARS-CoV2.6±3.7 )12.5±4.4 (µg/ml(Kumaki et al., 2011; Liu et al., 2008)Papaverine (N), alkaloid **(48)***Papaver somniferum* L.Inhibits viral replicationHCoV-OC431.61 (12.11) µM(Labanca et al., 2018; Shen et al., 2019)HCoV-NL637.32 (11.71) µMMERS-CoV9.45 (11.98) µMMHV-A5911.46 (12.44) µMPapyriflavonol A (N), flavonoid **(49)***B. papyrifera*tInhibits coronavirus proteases enzymeMERS-CoV112.5±7.3 µM(Park et al., 2017)SARS-CoV103.6±17.4µMPinusolidic acid, (N), diterpenoid **(50)***C. obtuse* var.Inhibits viral replicationSARS-CoV4.71 (\>750) µM(Wen et al., 2007)Pristimerin (N), triterpenoid **(51)**\
*Pristimerae indica,*\
*Tripterygium regelii*Inhibits viral replicationHCoV-OC431.99 (\>20) µM(Li et al., 2019; Ryu et al., 2010; Shen et al., 2019)HCoV-NL631.63 (\>20) µMMERS-CoV13.87 (\>20) µMMHV-A599.17 (\>20) µMSARS-CoV5.5 µMSaikosaponin A (N), triterpenoid saponins **(52)***Bupleurum* spp., *Heteromorpha* spp.,\
*Scrophularia scorodonia*Inhibits viral attachment and penetration into cellsHCoV-229E8.6±0.3 (228.1±3.8) µmol/L(Cheng et al., 2006)Saikosaponin B2 (N), triterpenoid saponins **(53)**\
*Bupleurum* spp., *Heteromorpha* spp., *S. scorodonia*Inhibits viral attachment and penetration into cellsHCoV-229E1.7±0.1 (383.3±0.2) µmol/L(Cheng et al., 2006)Saikosaponin C (N), triterpenoid saponins **(54)**\
*Bupleurum* spp., *Heteromorpha* spp., *S. scorodonia*Inhibits viral attachment and penetration into cellsHCoV-229E19.9±0.1 (121.5±0.1) µmol/L(Cheng et al., 2006)Saikosaponin D (N), triterpenoid saponins **(55)***Bupleurum* spp., *Heteromorpha* spp., *S. scorodonia*Inhibits viral attachment and penetration into cellsHCoV-229E13.2±0.3 (176.2±0.2) µmol/L(Cheng et al., 2006)Savinin (N), lignoid **(56)***C. obtuse* var.Inhibits viral replication\
Inhibits enzymatic activity of virusSARS-CoV25, 1.13, (\>750) µM(Wen et al., 2007)Sinigrin (N), glycoside **(57)***I. indigotica*Inhibits enzymatic activity of virusSARS-CoV217 (\>10,000) µM(Lin et al., 2005)Tetrandrine, (N), (bis-benzylisoquinoline alkaloids) **(58)***Stephania tetrandra*Inhibits viral S and N protein expressionHCoV-229E295.6 nM(Kim et al., 2019)Tetra-*O*-galloyl-D-glucose (N), tannin **(59)***Galla chinensis* L.Inhibits entry of virus to cellSARS-CoV\
4.5 µM (1.08 mM)(Yi et al., 2004)Tomentin A (N), coumarin **(60)***Paulownia tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV6.2±0.04 µM(Cho et al., 2013)Tomentin B (N), coumarin **(61)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV6.1±0.02 µM(Cho et al., 2013)Tomentin C (N), coumarin **(62)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV11.6±0.13 µM(Cho et al., 2013)Tomentin D (N), coumarin **(63)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV12.5±0.22 µM(Cho et al., 2013)Tomentin E (N), coumarin **(64)***P. tomentosa* (Thunb).Inhibits PLpro enzymeSARS-CoV5.0±0.06 µM(Cho et al., 2013)Tylophorine (N), alkaloid **(65)***T. indica*Inhibits viral replicationTGEV95±17 (\>100.000) nM(C.-W. Yang et al., 2010)Tylophorinine (N), alkaloid **(66)***T. indica* L.Inhibits viral replicationTGEV82 ±8 (\>100.000) nM(C.-W. Yang et al., 2010)α-cadinol, (N), sesquiterpenoid **(67)***C. obtuse* var.Inhibits viral replicationSARS-CoV4.44 (76.8) µM(Wen et al., 2007)**Marine**Esculetin-4-carboxylic acid ethyl ester (N), coumarin **(68)***Axinella cf. corrugate*, SpongeInhibit enzymatic activity of virusSARS-CoV\> 800 µmol L^-1^,\
112 µmol L^-1^(Lira et al., 2007)Halitunal (N), diterpene aldehyde **(69)***Hulimeda tuna*, AlgaeReduction in cell fusion and cytopathic effectsMurine coronavirus20 µg(Koehn et al., 1991)Mycalamide A (N), alkaloid **(70)***Mycale* sp.,\
SpongeProtein synthesis inhibitors of virusMHV-A59\
Tested dose 0.2µg/kg daily(Donia and Hamann, 2003)**Microorganisms**Antimycin A (N), alkaloid **(71)**\
*Streptomyces* spp.,\
BacteriaAntibioticHCoV-OC431.65 (3.62) µM(Shen et al., 2019; Van Tamelen et al., 1961)HCoV-NL636.05 (4.21) µMMERS-CoV6.89 (4.32) µMMHV-A595.42 (3.98) µMCycloheximide (N), alkaloid **(72)***Streptomyces* spp., BacteriaProtein synthesis inhibitorHCoV-OC430.43 (3.12) µM(Shen et al., 2019; Sisler and Siegel, 1967)HCoV-NL632.64 (3.24) µMMERS-CoV2.56 (2.96) µMMHV-A595.21 (3.19) µMMonensin sodium (ND), salt **(73)***Streptomyces cinnamonensis*, BacteriaInhibit viral replicationHCoV-OC433.81 (\>20) µM(Łowicki and Huczyński, 2013; Pillaiyar et al., 2020; Shen et al., 2019)HCoV-NL631.54 (\>20) µMMERS-CoV3.27(\>20) µMMHV-A590.18 (\>20) µMMycophenolate mofetil (ND) **(74)***Penicillium* spp., FungusImmune suppressant, antineoplastic, antiviralHCoV-OC431.58 (3.43) µM(Bittencourt et al., 2000; Pillaiyar et al., 2020; Shen et al., 2019; Sollinger, 2004)HCoV-NL630.23 (3.01) µMMERS-CoV1.54 (3.17) µMMHV-A590.27 (3.33) µMMycophenolic acid (N) **(75)***Penicillium* spp., FungusImmune suppressant, antineoplastic, antiviralHCoV-OC431.95 (3.55) µM(Cinatl et al., 2003; Hart et al., 2014; Pillaiyar et al., 2020; Shen et al., 2019; Sollinger, 2004)HCoV-NL630.18 (3.44) µMMERS-CoV1.95 (3.21) µMMHV-A590.17 (4.18) µMSARS-CoV\>0.15Valinomycin (N), Peptide **(76)***Streptomyces* sp., BacteriaAntibioticHCoV-OC434.43 (6.15) µM(Cheng, 2006; Shen et al., 2019)HCoV-NL631.89 (4.12) µMMERS-CoV6.07 (5.88) µMMHV-A596.78 (5.11) µMOligomycin (N), Macrolide **(77)***Streptomyces* sp., BacteriaInhibits viral replicationHCoV-OC430.19 (6.56) µM(Shen et al., 2019; P. W. Yang et al., 2010)HCoV-NL632.63 (4.26) µMMERS-CoV0.21 (5.16) µMMHV-A596.43 (6.78) µM[^1]Table 2List of plants extracts used as anti-coronavirusesTable 2PlantsType of extractOrganism/ MechanismIC~50~ or EC~50~ (CC~50~) value ug/mLReferences*Artemisia annua* L., Whole plantEtOHSARS-CoV Reduces RNA replication34.5 (1053)([@bib0077])*Cassia tora* (CTH)EtOHSARS-CoV Inhibits viral replication Inhibits enzymatic activity8.43 (\>500)\>50([@bib0134])*Celastrus orbiculatus* Thunb.EtOHSARS-CoV\
NR19.4([@bib0068])EtOAcSARS-CoV\
NR17.8AqueousSARS-CoV\
NR38.7*Cibotium barometz* (CBE)EtOHSARS-CoV\
Inhibits viral replication Inhibits enzymatic activity8.42 (\>500)\>50([@bib0134])*C. barometz* (CBM)EtOHSARS-CoV\
Inhibits viral replication Inhibits enzymatic activity\>10 (\>500)39([@bib0134])*Dioscorea batatas* (DBM)EtOHSARS-CoV\
Inhibits viral replication Inhibits enzymatic activity8.06 (\>500)44([@bib0134])*Echinacea purpurea*, RootsAqueous ethanolSARS-CoV\
Inhibits viral replication50([@bib0116])MERS-CoV\
Inhibits viral replication50HCoV-229E\
Inhibits viral replication3.2*Gentiana scabra* (GSH), RhizomesEtOHSARS-CoV\
Inhibits viral replication Inhibits enzymatic activity8.70 (\>500)\>50([@bib0134])*J. oxycredrus*, BerriesEssential oilSARS-CoV\
Inhibits viral replication270([@bib0086])*L. nobilis*, BerriesEssential oilSARS-CoV\
Inhibits viral replication120([@bib0086])*Lindera aggregate Sims*, RootsEtOHSARS-CoV\
Reduces RNA replication88.2 (1374)([@bib0077])*Lycoris radiata* (L\'Hér.), StemEtOHSARS-CoV\
Reduces RNA replication2.4 (886.6)([@bib0077])*P. palaestina,* FruitsEssential oilSARS-CoV\
Inhibits viral replication\>1000([@bib0086])*Pyrrosia lingua Mirb*., LeavesCHCl₃SARS-CoV\
Reduce RNA replication43.2 (2378)([@bib0077])*T. orientalis*, FruitsEssential oilSARS-CoV\
Inhibits viral replication130([@bib0086])*Taxillus chinensis* (TCH)EtOHSARS-CoV\
Inhibits viral replication Inhibits enzymatic activity5.39 (\>500)\>50([@bib0134])*Toona sinensis Roem* LeavesAqueousSARS-CoV\
Inhibits viral replication30 (\>500)([@bib0014])Fig. 4Structures of isolated anti-viral compounds of plant origin and their derivativesFig 4Fig. 5Structures of isolated anti-viral compounds of marine origin or their derivativesFig 5Fig. 6Structures of isolated anti-viral compounds of microbial origin or their derivativesFig 6

Glycyrrhizin **(34)** is an active terpenoid saponin compound isolated from liquorice roots (*Glycyrrhiza glabra* L.). Liquorice roots have been used in traditional medicine as prophylactic agent for gastric and duodenal ulcers, anti-inflammatory, contraceptive, laxative, anti-asthmatic, galactagogue, and antiviral, and expectorant ([@bib0029]; [@bib0113]). Cinatl et al. demonstrated that glycyrrhizin inhibited SARS virus replication by inhibition of adsorption. The penetration of the virus at early steps of the replicative cycle was stopped at both concentrations of (EC~50~ of 300 mg/L) and CC~50~ value of \>20 000 mg/L in comparison to ribavirin (positive control) when greater than \>1000 that could not be tolerated by the target tissue or organs ([@bib0024]).

In 2005, Li and his co-authors tested around 200 Chinese medicinal plants against Severe Acute Respiratory Syndrome associated coronavirus (SARS-CoV) using MTS assay. The results demonstrated that 4 of the 200 plants extracts, namely *L. radiata* (L\'Hér.), *A. annua* L., *P. lingua* Mirb. and *L. aggregate* Sims, showed superior activity at EC~50~ of 2.4, 34.5, 43.2 and 88.2 µg/mL respectively compared with interferon alpha as a positive control (EC~50~ = 660.3 IU/mL). Four potent extracts recorded CC~50~ values ranged between 886.6±35.0 to 2378.0±87.3 µg/mL. CC~50~ was determined based on reducing cell viability by using different concentration of extracts. As *L. radiata* (L\'Hér.) was the most active one, it was subjected to fractionation and purification to find the most active compound, identified as lycorine **(45)**. Lycorine is an alkaloid compound that gave EC~50~ of 15.7 nM and CC~50~ value of 14980.0 nM against SARS-CoV ([@bib0077]). Lycorine have been investigated later against the other types of coronaviruses, HCoV-OC43, HCoV-NL63, MERS-CoV and MHV-A59 to give EC~50~ values ranging from 0.15 µM to 1.63 µM ([@bib0114]).

Emetine is a natural plant alkaloid of ipecac (*Carapichea ipecacuanha* L.), emetine dihydrochloride **(31)**, a derivative of emetine inhibiting the viral protein synthesis of coronaviruses, with an EC~50~ value of 0.12 to 1.43 µM. Emetine hydrochloride revealed the strongest anti-CoV activities against MERS-CoV and SARS-CoV with the lowest EC~50~ of 0.014 and 0.05 µM), whilst the activity against HCoV-NL63, HCoV-OC43, MERS-CoV and MHV-A59 showed EC~50~ values of 1.43 µM, 0.30, 0.34 and 0.12 µM respectively *via* blocking of viral propagation at an early stage of infection, thereby minimizing the chance of the virus to adapt and acquire drug resistance. It also has CC~50~ values of 3.63, 2.69, 3.08 and 3.51 µM respectively ([@bib0036]; [@bib0114]).

*Toona sinensis* Roem, is a Chinese traditional plant belonging to the Meliaceae family. In folk medicine, the leaves of the plant were used to treat gastric ulcers, enteritis, dysentery, cerebrovascular, and cardiovascular diseases ([@bib0061]). TSL-1, a fraction of the aqueous extract of the plant leaves showed anti-viral activity against SARS-coronavirus with EC~50~ of 30 µg/mL and CC~50~ value \>500 µg/mL *via* inhibition of the viral replication. Determination of CC~50~ takes place by decreasing the cell viability by 50% ([@bib0014]). Another study was conducted by Wen et al., where 200 plants were tested and only five of them, namely *Gentiana scabra, Dioscorea batatas, Cassia tora*, and *Taxillus chinensis*, exerted survival inhibition of SARS-CoV ([@bib0134]). The plants possess a wide range of folk applications including liver disorder, inflammation and pneumonia treatment ([@bib0080]; [@bib0097]; [@bib0104]; [@bib0155]). The potent inhibition of SARS-CoV viral enzymatic activity (SARS-CoV 3CL protease) occurred between 25-200 µg/ml and the most potent plants were *C. barometz* and *D. batatas* with IC~50~ value of 39 and 44 µg/ml respectively. The six plant extracts recorded the same CC~50~ value of \>500 µg/ml in comparison with valinomycin (positive control) that has value of 75.01 µg/mL. The determination of CC~50~ showed that reduction of cell viability by 50% and there was no effect on the growth of host cells, indicating the effectiveness and safety of these extracts ([@bib0134]).

*Celastrus orbiculatus* Thunb. family (Celastraceae), a Chinese herbal plant, traditionally used in the treatment of fever, chills, edema and bacterial infection ([@bib0141]), showed significant effect *via* inhibition of the 3CL^pro^ enzyme. Three different extracts (EtOH, EtOAc and water fraction) have been tested against SARS-CoV infection, and exhibited IC~50~ values of 19.4, 17.8 and 38.7μg/ml respectively ([@bib0068]). Similarly, hydroethanolic extraction of *Echinacea purpurea* plant roots showed potent activity against HCoV-229E, SARS-CoV and MERS-CoV with IC~50~ values of 3.2, 50 and 50 µg/ml respectively ([@bib0116]).

Furthermore, the essential oils of many plants play an important role against viral diseases *i.e. Laurus nobilis, Juniperus oxycedrus* ssp. *oxycedrus, Thuja orientalis, Cupressus sempervirens* ssp. *pyramidalis, Pistacia palaestina, Salvia officinalis*, and *Satureja thymbra*. The essential oils were investigated against SARS-CoV and HSV-1 viruses. The potent activity of *L. nobilis* oil was reported against SARS-CoV with IC~50~ value of 120 µg/mL. The plant oil is characterized by the excitation of *β*-ocimene, 1,8-cineole, α-pinene, and β-pinene as the principle constituents. These plants act *via* the inhibition of viral replication ([@bib0086]).

Marines natural products, *i.e*. halitunal **(69)**, mycalamide **(70)** and esculetin-4-carboxylic acid ethyl ester **(68)** showed antiviral activity against coronaviruses. Halitunal is a diterpene aldehyde isolated from the marine alga *Halimeda tuna*, known to exert an impact against murine coronavirus strain A59 at a dose of 20 µg by reduction of cell fusion ([@bib0066]). Mycalamide is an alkaloid compound isolated from the *Mycale* sp. sponge that inhibited the MHV-A59 coronavirus replication by blocking the protein synthesis ([@bib0033]). Additionally, esculetin-4-carboxylic acid ethyl ester, is a coumarin compound derived from the *Axinella* cf. *corrugate* sponge that down-regulates the SARS 3CL-protease ([@bib0084]).

*Streptomyces* spp. compounds including monensin sodium **(73)**, cycloheximide **(72)**, oligomycins **(77)**, valinomycin **(76)**, and antimycin A **(71)** were isolated and investigated in opposition to SARS-CoV-2. Monensin sodium is an antibacterial salt isolated from *Streptomyces cinnamonensi* actinobacteria culture containing glucose, soybean oil, and grit ([@bib0087]). Monensin sodium exhibited antiviral activity against diverse coronaviruses (EC~50~= 0.18-3.81 µM) ([@bib0114]). Formerly, monensin and monensin sodium inhibited avian infectious bronchitis virus replication by blocking glycoprotein transport to plasma membranes at the level of the Golgi complex ([@bib0001]; [@bib0096]) . Cycloheximide, oligomycins, valinomycin and antimycin A were used against a wide spectrum of Coronaviruses by inhibiting protein synthesis and viral replication with EC~50~ of (0.43-5.21), (0.19 -6.43), (1.89-6.78) and (1.65-6.89), respectively. As well these compounds recorded CC~50~ value range between (2.96- 3.24), (4.26-6.78), (4.12-6.15) and (3.62-4.32) respectively ([@bib0114]).

Mycophenolic acid (MPA) **(75)** was first isolated from *Penicillium* spp. fungi by Bartolomeo Gosio in 1893 and was reported to have an immunosuppressive activity against psoriasis ([@bib0120]). Recently, mycophenolic acid was investigated against different types of coronavirus using a high-throughput screening approach, where the MPA showed potent anti- MHV-A59 activity *in vitro* at an EC~50~ value of 0.17 µM compared to of HCoV-OC43, HCoV-NL63 and MERS-CoV (EC~50~ values ranging from 0.18 to 1.95 µM). The value of CC~50~ of MHV-A59 equals 4.18 µM that is greater than the values of HCoV-OC43, HCoV-NL63 and MERS-CoV ranging from 3.21 to 3.55 µM ([@bib0114]). Another promising MPA derivative called mycophenolate mofetil **(74)** was reported to be an immunosuppressant, antineoplastic, and antiviral agent against HCoV-OC43, HCoV-NL63, MERS-CoV and SARS-CoV at EC~50~ of 1.58, 0.23, 1.54 and 0.27 µM. The CC~50~ of this compound ranged from 3.01 to 3.43 µM. The two compounds have similar chemical structures, but MPA showed a higher activity against MHV-A59 (EC~50~ = 0.17 µM) ([@bib0114]).

Curative efficacy of clinical studies and approved drugs {#sec0008}
--------------------------------------------------------

For a long time, natural products and their molecular frameworks constitute valuable starting points or sources for drug discovery ([@bib0037]; [@bib0109]). In line with Newman and Cragg, the number of antiviral drugs approved by the FDA in the period between 1981 to 2019 are 186 drugs, among them 87 are vaccines like FluMist®, Invivac®, Bilive®, Anflu®, Afluria® and Optaflu®, and are used against the influenza virus, 26 are synthetic but the pharmacophores are natural products, 17 are biological sources like peptides and proteins and 6 are natural products derivatives such as Tamiflu®, zanamivir® and virreal®, 21 are synthetic drugs (NP pharmacophore)/ mimics of natural products and other19 compounds are synthetics ([@bib0094]).

Nowadays, there are 80 running and pending clinical trials in China in a serious attempt to find a potential treatment for COVID-19 ([@bib0090]). In 2020, several compounds isolated from natural products ([Figure 7](#fig0007){ref-type="fig"} ; [Table 3](#tbl0003){ref-type="table"} ) were tested against coronavirus (COVID-19), *i.e. Xiyanping* (Mix of **78** and **79**). *Xiyanping*, is a semi-synthetic product derived from the active components of the *Andrographis paniculata* plant, and licensed in China as an anti-inflammatory agent ([@bib0023]; [@bib0144]). *Xiyanping* injection was investigated on 426 patients diagnosed with moderate to severe SARS-CoV-2 infection, every patient was injected with 10-20 ml of *Xiyanping* at 500 mg per 20 mL daily plus lopinavir/ritonavir tablets and α-interferon nebulization. The stated drug (lopinavir/ritonavir) has the ability to inhibit protease and CYP3A metabolism thus showing antiviral properties ([@bib0034]) (ClinicalTrials.gov; NCT04275388)Fig. 7Structures of isolated compounds and their derivatives from natural products sources in clinical trial studies against COVID-19Fig 7Table. 3List of ongoing clinical trials of natural products-based drugs targeting (COVID-19).Table 3CompoundsNatural products originClinical trials/phase/ Type of the study/ No of participantsDose/ administration route/ Mechanism of actionReferencesClinicalTrials.govIdentifier(9-Dehydro-17-hydro-andrographolide (DHA) **(78)** and sodium 9-dehydro-17-hydro-andrographolide-19-yl sulfate(DHAS)) (ND), *Xiyanping* products **(79)***Andrographis paniculata*, plant2019 Novel Coronavirus Pneumonia/ Observational/ 426 P10-20 ml daily of *Xiyanping* plus lopinavir tablet or ritonavir tablet plus α-interferon nebulization, For 14 days/ injection(<https://clinicaltrials.gov>, NCT04275388)Chloroquine (S\*), alkaloid **(27)***Cinchona* spp., PlantCOVID19, Coronavirus, Acute Respiratory Illnesses/Interventional/ 40000 P10 mg/kg followed by155 mg daily (250 mg chloroquine phosphate salt or 200 mg of or hydroxychloroquine sulphate)/ for 3 m(<https://clinicaltrials.gov>, NCT04303507)SARS-CoV, Severe Acute Respiratory Syndrome (SARS) Pneumonia/ Phase 2/ Interventional / 440 P150 mg/ twice daily/ 10 days(<https://clinicaltrials.gov>, NCT04323527)Fingolimod (ND), Alkaloid **(80)***Isaria sinclairii*, FungusCoronavirus Disease (COVID-19)/ Phase 2/ Interventional/ 30P0.5 mg/ once daily, for three consecutive days/ oral / Effective agent against COVID-19 *via* an immunology modulation of phingosine-1-phosphate receptors(<https://clinicaltrials.gov>, NCT04280588)Methylprednisolone (ND), Steroid **(81)***Corynebacterium simplex*,BacteriaCOVID-19, Novel Coronavirus Pneumonia/ Interventional/ 86 P1mg/kg/day/for 7 days/ intravenous(<https://clinicaltrials.gov>, NCT04273321)COVID-19 Infections/ Phase 2/ Interventional/ 80 P40 mg/ 12h for 5 days(<https://clinicaltrials.gov>, NCT04244591)Tetrandrine (N), alkaloid **(58)***Stephania tetrandra*, PlantCorona Virus Disease 2019,COVID-19/ Phase 4/ Interventional/ 60 P60 mg QD for 1week(<https://clinicaltrials.gov>, NCT04308317)Tocilizumab (B), Protein **(82)**Interleukin-6 (IL-6) receptor antibody, Biological sourceCovid-19/ Observational/ 120 P8 mg/kg / once in 100 ml 0.9% saline solution and administered intravenously within no less than 60 minutes/ Blocking the inflammatory molecule interleukin-6, decreased systemic inflammation, improved survival rate, better hemodynamic and improved of respiratory distress(<https://clinicaltrials.gov>, NCT04306705)

Fingolimod (FTY720) **(80)**, another compound derived from myriocin (ISP-1), is a metabolite of the *Isaria sinclairii* fungus. Fingolimod has been approved by the regulatory authorities of the US, EU, Australia, and Russia, to treat the relapsing remitting multiple sclerosis. Fingolimod consequently represents the primary oral drug for treatment of this central nervous autoimmune disease ([@bib0055]). In China, the Fingolimod drug was tested with 30 patients infected with COVID-19. Every patient was given 0.5 mg of Fingolimod orally daily, for three consecutive days. Fingolimod was used in the current study as an effective agent against COVID-19 acting via an immunology modulation of phingosine-1-phosphate receptors (ClinicalTrials.gov; NCT04280588) ([@bib0034]).

Tetrandrine **(58)** represents the predominant constituent of the *Stephania tetrandra* plant, a Chinese traditional medicinal plant. Tetrandrine is bisbenzylisoquinoline alkaloid and recommended in the Chinese Pharmacopoeia as an analgesic and diuretic agent and also for treatment of hypertension and various other ailments like asthma, tuberculosis, dysentery, hyperglycemia, malaria, cancer and fever. It was also used against the Ebola virus infection ([@bib0007]). In the clinical studies, tetrandrine has been proven effective against COVID-19 via reducing the clinical progress, improving the prognosis, reducing the incidence of pulmonary fibrosis during rehabilitation, and improving patients\' quality of life (ClinicalTrials.gov; NCT04308317). Tetrandrine has shown potential in decreasing the entry of SARS-CoV-2 S pseudovirions ([@bib0100]). Tocilizumab **(82)**, is a humanized monoclonal antibody that interacts with the interleukin-6 receptor (IL-6R) and is nowadays approved by China\'s National Health Commission for the treatment of inflammation in patients with COVID-19 ([@bib0028]). Previously, Tocilizumab (Actemra®) was permitted by means of the FDA as a drug used for inflammatory bowel disease treatment ([@bib0094]). Recently, some physicians in Italy (Pascale Hospital, Naples) claimed that Actemra® (Tocilizumab) succeeded in treating severely ill patients via blocking the inflammatory molecule interleukin-6, decreasing systemic inflammation, improving survival rate, adjusting hemodynamic and relieving the respiratory distress ([@bib0030]).

Streptokinase and Heparin were investigated as a treatment for patients infected by Severe Acute Respiratory Syndrome (SARS) and Severe Acute Respiratory Distress Syndrome (ARDS), the first one is an enzyme isolated from the *Streptococci* bacteria and the other is a glycosaminoglycan derived from dog liver ([@bib0002]; [@bib0091]). The two compounds had been administrated in 40 patients infected with ARDS. The first 20 patients were treated with heparin (10.000 IU) and the other 20 were treated with Streptokinase (250.000 IU). Each drug was prepared in a 3 ml volume of distilled water and nebulized for a period of 15 min every 4 h. The outcome of the study revealed an improvement of the hypoxemia as determined by PaO~2~/FiO~2~ ratio \>100, an improvement of the pulmonary compliance of the patient defined as dynamic compliance \>50 ml/cm H~2~O, and a decrease of the occurrence of complications such as bleeding or coagulopathy within 72 h of initiation of therapy. Streptokinase and Heparin may prevent /or dissolve intra-alveolar fibrin clots respectively helping alveolar re-expansion (ClinicalTrials.gov; NCT03465085).

Methylprednisolone **(81)** is a natural products derivative (prednisolone derivative glucocorticoid) implemented by the FDA as an anticancer drug ([@bib0039]; [@bib0047]; [@bib0094]; [@bib0107]). In early 2020, two clinical studies had been conducted on methylprednisolone against SARS-CoV-2 with 86 and 80 participants respectively. In both studies, all participants recovered except for one case that died in the first study (ClinicalTrials.gov; NCT04273321; NCT04244591).

Chloroquine **(27)** is a synthetic drug but its pharmacophore is a natural product origin (Quinin isolated from *Cinchona spp.* plant) ([@bib0098]), and approved antiphrastic (anti-malaria) drug as per the FDA ([@bib0094]). In the 1960′s, it was investigated as an antiviral *in vitro* for the first time ([@bib0123]). Chloroquine was able to inhibit MERS-CoV replication at a very early stage of infection with EC~50~ of 3.0 µM, and it was reported as a potent anti-viral agent against flavivirus, influenza virus, HIV, Ebola virus, and Nipha-Hendravirus ([@bib0106]). Nevertheless, many clinical studies were conducted on chloroquine as an anti- COVID-19 virus agent (ClinicalTrials.gov; NCT04303507), and its efficacy and safety remain unclear. It is proven highly effective in blocking viral replication in other infections including the SARS-associated coronavirus (CoV) ([@bib0027]). However, in a recent observational study, hydroxychloroquine treated patient was more seriously ill than those who hadn\'t received hydroxychloroquine ([@bib0045]).

Patents of natural products prescriptions against COVID-19 pandemic {#sec0009}
-------------------------------------------------------------------

As discussed earlier, small-molecule, approved drugs, and natural products are promising entities to combat COVID-19 depending on various mechanisms of action. Traditional Chinese medicine (TCM) has a synergistic effect that plays a vital role in resisting the virus and resisting inflammation of the lung and thus some TCM formulas have been proposed and approved as patents against coronaviruses. Our review devotes to patents from natural product sources ([Table 4](#tbl0004){ref-type="table"} ).Table. 4List of patents on the treatment of COVID-19 by using Traditional Chinese MedicineTable 4InventorIngredients (parts by weight)/ Patent formTitle/ Publication number/ Patent officeType of virus/ Effective rate or (cure rate)/ Mode of actionReferencesChinese name:\
[葛又文](https://patents.google.com/?inventor=%E8%91%9B%E5%8F%88%E6%96%87){#interref0010}\
English name: Ge Youwen9 parts of ephedra, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of *Gypsum*, 9 parts of *Cassia* Twig, 9 parts of Rhizoma Alismatis, 9 parts of *Grifola*, 9 parts of bighead *Atractylodes* rhizome, 15 parts of *Poria cocos*, 16 parts of Radix Bupleuri, 6 parts of *Scutellaria baicalensis*, 9 parts of ginger processed Pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of Flos Farae, 9 parts of blackberry lily, 6 parts of *Asarum*, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled *Gianthyssop* herb/ **Decoction**Prescription for treating pneumonia caused by novel coronavirus infection and application thereof /\
(CN110870402A)/ CNSARS-CoV-2/\
95.12%/ Treating pneumonia(Ge, 2020)Chinese name:\
[张宁](https://patents.google.com/?inventor=%E5%BC%A0%E5%AE%81){#interref0011} and [杨海军](https://patents.google.com/?inventor=%E6%9D%A8%E6%B5%B7%E5%86%9B){#interref0012}\
English name:\
Zhang Ning and Yang Haijun40 parts of Folium Isatidis, 40 parts of the wild *Chrysanthemum* flower, 20 parts of *Coptis chinensis*, 30 parts of sweetsop seed, 20 parts of wrinkled *Gianthyssop* herb, 20 parts of Rhizoma Atractylodis, 20 parts of Radix Bupleuri, 2 parts of Calculus Bovis Factitius, 20 parts of *Houttuynia cordata*, 5 parts of dandelion root, 30 parts of honeysuckle, 30 parts of Fructus Forsythiae, 20 parts of *Scutellaria baicalensis*, 20 parts of blackberry lily, 15 parts of *Salvia miltiorrhiza*, 15 parts of Bulbus Fritillariae Cirrhosae, 10 parts of *Saussurea involucrate*, 60 parts of *Astragalus mongholicus*, 20 parts of *Cordyceps sinensis*, 20 parts of *Codonopsis*/ **Tablet, capsule, granule, pill or oral liquid.**Traditional Chinese medicine composition with function of resisting novel coronavirus sars-cov-2 and preparation method and application thereof/\
**Bibliography**\
There are no sources in the current document.\
(CN111150792A)/ CNSARS-CoV-2/\
Not reported/\
Improve the pneumonia symptom(Zhang, Ning., Yang, 2020)Chinese name: [雷鸣](https://patents.google.com/?inventor=%E9%9B%B7%E9%B8%A3){#interref0013} and [养立](https://patents.google.com/?inventor=%E5%85%BB%E7%AB%8B){#interref0014}English name:\
Lei Ming and Yang Li33-15 parts of *Tripterygium wilfordii*, 10-50 parts of *Gypsum*, 8-24 parts of raw Chinese yam, 5-15 parts of Radix Scrophulariae, 4-12 parts of Fructus Forsythiae, 4-10 parts of Periostracum Cicada, 4-12 parts of *Codonopsis pilosula*, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre/ **Not reported**Traditional Chinese medicine composition and application thereof/ (CN111184805A)/ CNSARS-Cov-2/Not reported/Regulating immunity and utilized to treating SARS-Cov-2(Lei, Ming; Yang, 2020)Chinese name: [吴通武](https://patents.google.com/?inventor=%E5%90%B4%E9%80%9A%E6%AD%A6){#interref0015}, [梁力](https://patents.google.com/?inventor=%E6%A2%81%E5%8A%9B){#interref0016}, [张堂江](https://patents.google.com/?inventor=%E5%BC%A0%E5%A0%82%E6%B1%9F){#interref0017} and [梁洪海](https://patents.google.com/?inventor=%E6%A2%81%E6%B4%AA%E6%B5%B7){#interref0018}\
English name:\
Wu Tongwu, Liang Li, Zhang Tangjiang and Liang Honghai15-45 parts of prepared aconite, 10-30 parts of dried ginger, 30-60 parts of honey-fried licorice root, 15-30 parts of American ginseng, 10-30 parts of *Ephedra*, 15-30 parts of *Cassia* twig, 5-10 parts of *Asarum*, 10-70 parts of honeysuckle flower, 10-30 parts of Fructus Forsythiae, 10-30 parts of *Isatis* root, 10-30 parts of reed rhizome, 15-30 parts of Folium Isatidis, 20-240 parts of *Gypsum*, 10-30 parts of lalang grass rhizome, 10-15 parts of Rhizoma Paridis, 5-15 parts of wrinkled *Gianthyssop* herb, 5-10 parts of *Eupatorium*, 5-10 parts of safflower, 5-15 parts of Cortex Moutan, 5-15 parts of *Rheum officinale*, 15-45 parts of ginger, 10-30 parts of Chinese date and 5-9 parts of musk/ **Liquid**Traditional Chinese medicine formula for treating or preventing novel coronavirus pneumonia and viral influenza/ (CN111110819A)/ CNSARS-CoV-2/(80%)/ Improving human immunity and prevention or treatment of SARS-Cov-2(Wu, Tongwu; Liang, Li; Zhang, Tangjiang; Liang, 2020)Chinese name:\
[潘耀宗](https://patents.google.com/?inventor=%E6%BD%98%E8%80%80%E5%AE%97){#interref0019}, [王恒斌](https://patents.google.com/?inventor=%E7%8E%8B%E6%81%92%E6%96%8C){#interref0020}, [张丹丹](https://patents.google.com/patent/CN111150755A/en?oq=CN111150755A){#interref0021}, [张邦国](https://patents.google.com/patent/CN111150755A/en?oq=CN111150755A){#interref0022}, [李全](https://patents.google.com/patent/CN111150755A/en?oq=CN111150755A){#interref0023}, [罗年翠](https://patents.google.com/patent/CN111150755A/en?oq=CN111150755A){#interref0024}, [曹泽庆](https://patents.google.com/?inventor=%E6%9B%B9%E6%B3%BD%E5%BA%86){#interref0025} and [翟云良](https://patents.google.com/?inventor=%E7%BF%9F%E4%BA%91%E8%89%AF){#interref0026}\
English name:\
Pan Yaozong, Wang Hengbin, Zhang Dandan, Zhang Bangguo, Li Quan, Luo Niancui, Cao Zeqing and Zhai Yunliang40 parts of wrinkled *Gianthyssop* herb, 40 parts of wild *Chrysanthemum* flower, 24 parts of Chinese mosla herb and 40 parts of sweet wormwood herb/ **Tablets, capsules, pills, oral liquid, or mixtures.**Chinese medicine composition for preventing and treating viral diseases and application thereof/ (CN111150755A)/ CNSARS-CoV-2/Not reported/\
Inhibiting cytokine expression *i.e.* TNF- α and IL-6 produced by SARS-Cov-2(Pan, Yaozong., Wang, Hengbin., Zhang, Dandan., Zhang, Bangguo., Li, Quan., Luo, Niancui., Cao, Zeqing., Zhai, 2020)Chinese name:\
[王学昌](https://patents.google.com/?inventor=%E7%8E%8B%E5%AD%A6%E6%98%8C){#interref0027}, [张董喆](https://patents.google.com/?inventor=%E5%BC%A0%E8%91%A3%E5%96%86){#interref0028}and [程少丹](https://patents.google.com/?inventor=%E7%A8%8B%E5%B0%91%E4%B8%B9){#interref0029}\
English name:\
Wang xuechang, Zhang Dongzhe and Cheng Shaodan50-80 parts of clove, 20-30 parts of Cacumen Biotae and 15-20 parts of *Angelica dahurica*; 10-15 parts of honeysuckle; 10-15 parts of *Agastache rugosus*, 10-15 parts of *Eupatorium fortunei*, 10-15 parts of *Cassia* twig, 10-15 parts of camphor, 10-15 parts of *Saposhnikovia divaricate* root, 10-15 parts of isatis root, 10-15 parts of folium *Artemisiae argyi* and 10-15 parts of borneol/ **Capsule**Sachet for efficiently preventing novel coronavirus pneumonia and influenza/ (CN111214689A)/ CNSARS-CoV-2/\
Not reported/\
Preventing novel coronavirus pneumonia and preventing and treating respiratory diseases(Wang, Xuechang; Zhang, Dongzhe; Cheng, 2020)Chinese name:\
[张涛涛](https://patents.google.com/?inventor=%E5%BC%A0%E6%B6%9B%E6%B6%9B){#interref0030}, [何莉华](https://patents.google.com/?inventor=%E4%BD%95%E8%8E%89%E5%8D%8E){#interref0031} and [彭严](https://patents.google.com/patent/CN111214637A/en?oq=CN111214637A){#interref0032}\
English name:\
Zhang Taotao, He Lihua and Peng Yan3-18 parts of *Ephedra*, 2-10 parts of liquorice, 3-18 parts of almond, 5-45 parts of *Gypsum* (decocted first), 3-18 parts of *Cassia* twig, 3-18 parts of Rhizoma Alismatis, 3-18 parts of *Grifola*, 3-18 parts of bighead *Atractylodes* rhizome, 5-25 parts of *Poria cocos*, 6-26 parts of Radix Bupleuri, 2-10 parts of *Scutellaria baicalensis*, 3-18 parts of ginger *Pinellia ternata*, 3-18 parts of ginger, 3-18 parts of aster, 3-18 parts of Flos Farfarae, 3-18 parts of blackberry lily, 2-10 parts of *Asarum*, 6-18 parts of Chinese yam, 2-10 parts of immature bitter orange, 2-10 parts of dried orange peel, 2-10 parts of Rhizoma Atractylodis, and the like, 3-18 parts of *Agastache rugosus*/ **Tablets, powder, soft capsules, syrup, pills and granules.**Traditional Chinese medicine composition and preparation method and pharmaceutical application thereof/ (CN111214637A) /CNSARS-CoV-2/\
Not reported/\
Treating or preventing the new coronavirus 2019-nCoV(Zhang, Taotao; He, Lihua; Peng, 2020)Chinese name:\
[奚肇庆](https://patents.google.com/?inventor=%E5%A5%9A%E8%82%87%E5%BA%86){#interref0033}, [束雅春](https://patents.google.com/patent/CN111214566A/en?oq=CN111214566A){#interref0034}, [刘志辉](https://patents.google.com/patent/CN111214566A/en?oq=CN111214566A){#interref0035}, [马朝群](https://patents.google.com/patent/CN111214566A/en?oq=CN111214566A){#interref0036}, [汪悦](https://patents.google.com/patent/CN111214566A/en?oq=CN111214566A){#interref0037}, [史锁芳](https://patents.google.com/patent/CN111214566A/en?oq=CN111214566A){#interref0038}, [乔飞](https://patents.google.com/patent/CN111214566A/en?oq=CN111214566A){#interref0039}, [吴磊](https://patents.google.com/?inventor=%E5%90%B4%E7%A3%8A){#interref0040} and [吴旭彤](https://patents.google.com/patent/CN111214566A/en?oq=CN111214566A){#interref0041}\
English name:\
Xi Zhaoqing, Shu Yachun, Liu Zhihui, Ma Chaoqun, Wang Yue, Shi Suofang, Qiao Fei, Wu Lei and Wu Xutong6-30 parts of *Astragalus membranaceus*, 6-30 parts of *Codonopsis pilosula*, 5-18 parts of bran-fried bighead *Atractylodes* rhizome, 6-15 parts of *Poria cocos*, 3-30 parts of *Perilla* leaf, 3-15 parts of *Saposhnikovia divaricata* root, 3-20 parts of dried orange peel, 2-15 parts of Chinese date and 2-9 parts of liquorice/ **Extract, granules, capsules or pills**Epidemic prevention traditional Chinese medicine composition and preparation method and application thereof/ (CN111214566A)/ CNSARS-CoV-2/\
Not reported/ Prevent the infection of the new coronavirus SARS-CoV-2(Xi, Zhaoqing; Shu, Yachun; Liu, Zhihui; Ma, Chaoqun; Wang, Yue; Shi, Suofang; Qiao, Fei; Wu, Lei; Wu, 2020)Chinese name:\
[杨汉梅](https://patents.google.com/?inventor=%E6%9D%A8%E6%B1%89%E6%A2%85){#interref0042}, [陈彩虹](https://patents.google.com/?inventor=%E9%99%88%E5%BD%A9%E8%99%B9){#interref0043},[陈天跃](https://patents.google.com/?inventor=%E9%99%88%E5%A4%A9%E8%B7%83){#interref0044} and [杨仪鏐](https://patents.google.com/?inventor=%E6%9D%A8%E4%BB%AA%E9%8F%90){#interref0045}\
English name: Yang Hanmei, Chen Caihong, Chen Tianyue and Yang Yiliao8-12 parts of *semiliquidambar cathayensis*, 8-12 parts of *cinnamomum camphora* root, 8-12 parts of citronella, 8-12 parts of *Sculellaria barbata*, 8-12 parts of giant knotweed rhizome, 8-12 parts of honeysuckle stem, 8-12 parts of weeping forsythia, 8-12 parts of dandelion, 8-12 parts of radix bupleuri, 8-12 parts of *Cnanchum glaucescens*, 8-12 parts of bitter apricot kernel, 8-12 parts of aster, 8-12 parts of reed rhizome and 8-12 parts of euphorbia lathyrism/ **Pills**Fumigation bath preparation for preventing and treating pestilence, and its application method and application/ (CN111184823A)/ CNSARS-CoV-2/ 90% (80%)/ Improve human immunity and has prevention and treatment effects on new coronavirus pneumonia(Yang, Hanmei; Chen, Caihong; Chen, Tianyue; Yang, 2020)Chinese name: [陈文才](https://patents.google.com/?inventor=%E9%99%88%E6%96%87%E6%89%8D){#interref0046} English name: Chen Wencai20-100 g of *Laggera pterodonta*, 10-50 g of honeysuckle, 10-30 g of dried ginger, 10-40 g of divaricate saposhnikovia root, 10-50 g of *Officinal magnolia* bark and 10-60 g of pilose asiabell root/ **liquid**Laggera pterodonta composition for treating new COVID-19 and application thereof/ (CN111166862A)/ CNSARS-CoV-2/ Not reported / Preventing and treating infectious plague and common respiratory diseases, resisting virus and enhancing immunity(Chen, 2020)

One prescription for treating pneumonia caused by the new coronavirus infection was inspired by the TCM composition and discloses. The prescription raw materials combine, parts by weight, of the following TCM materials: 9 parts of *Ephedra*, 6 parts of honey-fried licorice root, 9 parts of almond, 15-30 parts of *Gypsum*, 9 parts of *Cassia* Twig, 9 parts of Rhizoma Alismatis, 9 parts of *Frifola*, 9 parts of bighead *Atractylodes* rhizome, 15 parts of *Poria cocos*, 16 parts of *Radix Bupleuri*, 6 parts of *Scutellaria baicalensis*, 9 parts of ginger processed Pinellia tuber, 9 parts of ginger, 9 parts of aster, 9 parts of Flos Farae, 9 parts of *Blackberry lily*, 6 parts of *Asarum*, 12 parts of Chinese yam, 6 parts of immature bitter orange, 6 parts of dried orange peel and 9 parts of wrinkled *Gianthyssop* herb. The effective rate of treatment was reported to 95%. The percent of effective rates was calculated based on the number of confirmed diagnosis and the number of treated patients from different places. This patent was documented in patent office CN with publication number (CN110870402A) ([@bib0044]).

Another TCM prescription is composed of the following raw materials in parts by weight: 40 parts of Folium isatidis, 40 parts of the wild *Chrysanthemum* flower, 20 parts of *Coptis chinensis*, 30 parts of sweetsop seed, 20 parts of wrinkled *Gianthyssop* herb, 20 parts of Rhizoma Atractylodis, 20 parts of Radix Bupleuri, 2 parts of Calculus Bovis Factitius, 20 parts of *Houttuynia cordata*, 5 parts of dandelion root, 30 parts of honeysuckle, 30 parts of Fructus Forsythiae, 20 parts of *Scutellaria baicalensis*, 20 parts of blackberry lily, 15 parts of *Salvia miltiorrhiza*, 15 parts of Bulbus Fritillariae Cirrhosae, 10 parts of *Saussurea involucrate*, 60 parts of *Astragalus mongholicus*, 20 parts of *Cordyceps sinensis*, 20 parts of *Codonopsis*. Observation of clinical experiments shows that the patent boosted the pneumonia symptoms caused by the new SARS-Cov-2 coronavirus. This patent was documented in patent office CN with publication number (CN111150792A) (Zhang, Ning., Yang, 2020).

*Tripterygium wilfordii* is the main formula for one of the TCM patents. The composition of this patent has the following raw materials as parts by weight: 3-15 parts of *Tripterygium wilfordii*, 10-50 parts of *Gypsum*, 8-24 parts of raw Chinese yam, 5-15 parts of Radix Scrophulariae, 4-12 parts of Fructus Forsythiae, 4-10 parts of *Periostracum cicada*, 4-12 parts of *Codonopsis pilosula*, 3-8 parts of mint, 3-10 parts of burdock and 4-20 parts of raw ochre. This patent was claimed suitable for the severe stage of COVID-19 pneumonia diseases, regulating immunity and decreasing the fever. The administration rate of the prescription (3-5 times) can decrease body temperature to the normal range. *Tripterygium wilfordii* relates to Chinese herbal medicine, and used in traditional medicine for promoting blood circulation, killing parasites, regulating immunity, and has a good medicinal effect when utilized in treating 2019 new coronavirus pneumonia. This patent was documented in patent office CN with publication number (CN111184805A) (Lei, Ming; Yang, 2020).

One more patent that also relates to TCM, is possessing a formula for treating or preventing both novel coronavirus pneumonia and viral influenza. This formula combines raw materials, parts by weight, as a following: 15-45 parts of prepared aconite, 10-30 parts of dried ginger, 30-60 parts of honey-fried licorice root, 15-30 parts of American ginseng, 10-30 parts of *Ephedra*, 15-30 parts of *Cassia* twig, 5-10 parts of *Asarum*, 10-70 parts of honeysuckle flower, 10-30 parts of Fructus Forsythiae, 10-30 parts of *Isatis* root, 10-30 parts of reed rhizome, 15-30 parts of Folium Isatidis, 20-240 parts of *Gypsum*, 10-30 parts of lalang grass rhizome, 10-15 parts of Rhizoma Paridis, 5-15 parts of wrinkled *Gianthyssop* herb, 5-10 parts of *Eupatorium*, 5-10 parts of safflower, 5-15 parts of Cortex Moutan, 5-15 parts of *Rheum officinale*, 15-45 parts of ginger, 10-30 parts of Chinese date and 5-9 parts of musk. This patent has a corollary effect on ventilating lungs and improving human immunity. It was used for coronavirus, influenza, and pneumonia prevention or treatment. The findings showed that 24 patients out of 30 were cured and that this formula was helpful in treating the new coronavirus pneumonia effectively. The cure rate was estimated to 80%. This patent was documented in patent office CN with publication number (CN111110819A) (Wu, Tongwu; Liang, Li; Zhang, Tangjiang; Liang, 2020).

Another formula was studied *in vitro* against common coronavirus and new coronavirus. The formula composed of the following raw materials, as parts by weight: 40 parts of wrinkled *Gianthyssop* herb, 40 parts of wild *Chrysanthemum* flower, 24 parts of Chinese mosla herb and 40 parts of sweet wormwood herb. This formula has a potent effect on inhibiting cytokine expression *i.e.* TNF- α and IL-6 produced by SARS-Cov-2. The formula was used earlier as a therapeutic agent against pneumonia, nephritis, hepatitis. It has very good prospects for clinical application and thus it was approved from CN patent office under publication number (CN111150755A) (Pan, Yaozong., Wang, Hengbin., Zhang, Dandan., Zhang, Bangguo., Li, Quan., Luo, Niancui., Cao, Zeqing., Zhai, 2020).

The protective role of plants and their constituents against COVID-19 {#sec0010}
=====================================================================

The consumption of healthy diets is one way to boost the immune system and in return help in fighting off viruses ([@bib0042]). There is a wide range of plants that contribute to boosting the immune system given their high content of a wide variety of nutrients and biological active compounds ([@bib0121]). A strong immune system is essential for fighting against COVID-19. COVID-19 seems to be hazardous for people with comorbidities and those have a weaker immune system than healthy ones (N. [@bib0016]; [@bib0059]). Garlic stimulates the immune system as it is rich with a wide plethora of nutrients, vitamins, and sulfur-containing compounds ([@bib0054]). Certain vegetables such as broccoli, spinach and sweet potatoes are abundant with vitamin A which include retinol, retinoic acid and β-carotene. These fat-soluble compounds participate in enhancement of the immune function. Additionally, isotretinoin (vitamin A derivative), inhibits ACE2 and the entry of SARS-COV-2 into the body thereby lower the susceptibility to infections ([@bib0042]). Citrus fruits are one of the best sources for vitamin C. Vitamin C increases the production of white blood cells providing a key role in fighting infections ([@bib0010]). Vitamins are recommended for the protection against coronavirus as they increase patients\' resistance against infection ([@bib0005]).

Conclusions {#sec0011}
===========

The outbreak of COVID-19 has swept across the world rapidly spreading in a very alarming pace invading more than 200 countries, territories, areas leaving a trail of victims behind. Although SARS-CoV-2 is accompanied by symptoms similar to that of SARS-CoV-2 *i.e.* fever, cough, and fatigue, SARS-CoV-2 is far more contagious. It can be transmitted by droplets or close contact. Given the affinity by which SARS-CoV-2 protein S can bind to ACE2 receptors, human to human transmission seems to spread much faster than the common flu or even the previous coronaviruses. Thus, containing the outbreak is a burning issue requires extensive measures and developing specific safe drugs. Natural products have so far proven to be promising for the development of effective and less toxic antiviral agents. Owing to the genetic resemblance between coronaviruses, the drugs and antiviral agents which are usually effective against the other types of coronaviruses could be used to treat COVID-19. Some of the reported antivirals showed a promising antiviral activity against at least four types of human coronaviruses with significant EC~50~ and CC~50~ values. Other therapeutic agents have also been reported and are already moving into clinical trials including *Xiyanping*, fingolimod, methylprednisolone, streptokinase, and heparin.
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